The briefing
Targeted Oncology features Jorge Nieva, MD, discussing how extended responses in ROS1-positive non–small cell lung cancer influence imaging frequency, minimal residual disease testing, and decisions on treatment intensification. These insights could refine monitoring strategies for long-term responders.
Original headline
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC